| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $113K | — |
| R&D Expense | $601K | -21.0% |
| SG&A Expense | $9.6M | +171.7% |
| Pre-tax Income | -$12.8M | -182.7% |
| Net Income | -$12.8M | -182.7% |
| EPS (Basic) | -$0.40 | -150.0% |
| EPS (Diluted) | -$0.40 | -150.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $8.20B | — |
| Short-term Investments | $8.20B | — |
| Accounts Receivable | $5K | — |
| Current Assets | $2.3M | +274.4% |
| Total Assets | $10.9M | +1006.6% |
| Current Liabilities | $6.7M | +243.2% |
| Total Liabilities | $8.5M | +329.0% |
| Stockholders' Equity |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$8.3M | -260.5% |
| Capital Expenditures | $495K | +1197.8% |
| Investing Cash Flow | -$362K | -215.8% |
| Financing Cash Flow | $10.6M | +379.7% |
| Free Cash Flow | -$8.7M | -275.9% |
| $2.5M |
| +351.8% |